NEO Investors Have Opportunity to Lead NeoGenomics, Inc. Securities Fraud Lawsuit

11:00 am ET January 26, 2023 (PR Newswire) Print

Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO).

Class Period: February 27, 2020 - April 26, 2022

Lead Plaintiff Deadline: February 6, 2023

If you wish to serve as lead plaintiff of the NeoGenomics lawsuit, you can submit your contact information at www.glancylaw.com/cases/neogenomics-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investorsthat: (1) NeoGenomics was anything but a "one-stop-shop" for cancer testing because it did not offer the most technologically advanced NGS tests, which led to a significant decrease in revenue as current and prospective customers went elsewhere for their testing needs; (2) the Company's costs were not fixed because NeoGenomics needed to hire additional employees to process more complex customized testing demanded by customers utilizing the Company's outdated portfolio of tests, leading to operational challenges, decreased lab efficiency, and increased testing turnaround times; (3) NeoGenomics violated federal healthcare laws and regulations related to fraud, waste, and abuse; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish tolearn moreabout this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

https://c212.net/c/img/favicon.png?sn=LA97263&sd=2023-01-26

View original content:https://www.prnewswire.com/news-releases/neo-investors-have-opportunity-to-lead-neogenomics-inc-securities-fraud-lawsuit-301731231.html

SOURCE Glancy Prongay & Murray LLP

https://rt.newswire.ca/rt.gif?NewsItemId=LA97263&Transmission_Id=202301261100PR_NEWS_USPR_____LA97263&DateId=20230126

COMTEX_423348206/1005/2023-01-26T11:00:12